Vaccines are one of the most successful and cost-effective global health interventions, preventing millions of deaths worldwide each year. According to WHO statistics, the supply of vaccines in 2021 is up to about 16 billion doses, with a total value of US $141 billion, which is almost three times the vaccine market supply in 2019 (5.8 billion doses) and nearly three and a half times the market value in 2019 (US $38 billion). This increase was mainly driven by the COVID-19 of vaccines. This demonstrates the great potential of scaling up vaccine production for health needs. At the same time, there are still large unmet medical needs in the vaccine field, including the need to develop vaccines with broader protection, as well as new vaccines against pathogens for which no vaccine has been approved.

Innovative vaccines and Pfizer PK, leveraging the $7 billion market

In the whole vaccine field, the development of bacterial vaccines is difficult because of the high complexity of bacteria, the diversity of pathogenic mechanisms and the difficulty of antigen selection. Therefore, in most cases, bacterial vaccines are composed of multiple complex components, and the interaction of multiple factors needs to be considered, which is difficult to develop.

On the other hand, the use of antibiotics has weakened people's awareness of the prevention of bacterial infections. In recent years, the emergence of bacterial resistance has made traditional antibiotics unable to play a role in some cases. In addition, the development cycle of antibiotics is long, and the development of new antibiotics is lagging behind. As an effective means to prevent bacterial infection, bacterial vaccine can reduce the occurrence of infectious diseases and the use of antibiotics, and its importance is becoming more and more prominent.

among them,pneumococcal disease(PD) has been listed by the World Health Organization as a disease requiring "very high priority" vaccine prevention. Pneumococcal disease is one of the serious public health problems in the world, and it is also an important cause of morbidity and mortality of children and adults in China. At present, the problem of drug resistance of pneumococci is becoming more and more serious. Therefore, it is particularly necessary and urgent to use pneumococcal vaccine to prevent pneumococcal diseases and reduce bacterial drug resistance.

At present, the global pneumococcal vaccine market is dominated by Pfizer's Pei Er series vaccine (Prevnarfamily) (mainly including Prevnar/Prevenar13 & 20). As the world's best-selling vaccine product, Pei Er vaccine has a sales volume of US $6.337 billion in 2022, which is one of the world's highest non-new crown vaccine products in 2022, accounting for about 14% of the world's non-new crown vaccine sales volume, with a sales volume of US $4.835 billion in the first three quarters of 2023. Although there have been Mercadon at home and abroad,Watson Creatures(23.130, -0.47, -1.99%), Amy Weixin, Minhai Bio and other manufacturers into the bureau, but the market position of Pei Er vaccine has not been shaken.